PatientsLikeMe has unveiled a suite of services for pharmaceutical companies that allows them to collaborate with patients on the design of clinical trials and other research.
PatientsLikeMe has unveiled a suite of services for pharmaceutical companies that allows them to collaborate with patients on the design of clinical trials and other research. The announcement was made at the 50th annual meeting of the Drug Information Association (DIA) in San Diego, where global leaders in drug development and regulation are discussing new ways to accelerate the development of patient-centered health solutions.
Vice President of Innovation Paul Wicks, Ph.D. said that with more than 250,000 members reporting on their experiences with 2,000 diseases, PatientsLikeMe has transformed the way patients can shape research. “We’ve nurtured an open, data-sharing environment where members share their experiences to live better, and built a foundation for pharma-patient partnerships that can truly advance medicine. By listening to patients, we can create actionable insights that optimize the design of trial protocols and bring about better treatments, faster.”
The launch comes as results from a March 2014 survey of PatientsLikeMe members reveal just how broken the trial process is, and how eager patients are to help fix it. Members were asked about their attitudes toward, experiences with and criteria for participating in clinical trials. Of 1,621 survey respondents:
The full survey results are being presented at DIA’s Professional Poster Session at location T44 on Tuesday, June 17, 2014.
PatientsLikeMe announced three services at DIA:
For more information, visit
www.patientslikeme.com/services
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.